Compare Edwards Lifesciences Corporation Common Stock (EW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Zoetis Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Edwards Lifesciences Corporation Common Stock is the larger of the two by market cap, and Zoetis Inc pays a 2.96% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | ZTS | |
|---|---|---|
Market Cap | $49.44B | $29.57B |
Volume | 3,508,027 | 4,128,093 |
Sector | Health | Health |
52-Week High | $95.18 | $147.53 |
52-Week Low | $72.65 | $69.09 |
Enterprise Value | $45.90B | $37.13B |
Typical Hold Time | — | 70 Days |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
